BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8641639)

  • 1. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study.
    Molica S; Musto P; Chiurazzi F; Specchia G; Brugiatelli M; Cicoira L; Levato D; Nobile F; Carotenuto M; Liso V; Rotoli B
    Haematologica; 1996; 81(2):121-6. PubMed ID: 8641639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immune globulin in chronic lymphocytic leukaemia.
    Gamm H; Huber C; Chapel H; Lee M; Ries F; Dicato MA
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):17-20. PubMed ID: 8033428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin replacement in chronic lymphocytic leukaemia.
    Bunch C
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):419-22. PubMed ID: 3065737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency.
    Favre O; Leimgruber A; Nicole A; Spertini F
    Allergy; 2005 Mar; 60(3):385-90. PubMed ID: 15679727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate.
    Castelli R; Vismara A; Pavia G; Dagani R; Porro T
    Ann Ital Med Int; 2002; 17(1):47-50. PubMed ID: 11975114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group.
    Giannini EH; Lovell DJ; Silverman ED; Sundel RP; Tague BL; Ruperto N
    J Rheumatol; 1996 May; 23(5):919-24. PubMed ID: 8724309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic and therapeutic use of immunoglobulin for intravenous administration in patients with secondary immunodeficiencies associated with malignancies.
    Morell A; Barandun S
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S87-91. PubMed ID: 2840630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections.
    Carbone J; Sarmiento E; Del Pozo N; Rodriguez-Molina JJ; Navarro J; Fernandez-Yañez J; Palomo J; Villa A; Muñoz P; Fernandez-Cruz E
    Clin Transplant; 2012; 26(3):E277-83. PubMed ID: 22686951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.
    Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E
    Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
    Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
    Drakos SG; Kfoury AG; Long JW; Stringham JC; Fuller TC; Nelson KE; Campbell BK; Gilbert EM; Renlund DG
    Ann Thorac Surg; 2006 Sep; 82(3):889-93. PubMed ID: 16928502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.